Vitamin D

• Ergocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.

• Ergocalciferol is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.contraindicated

THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW. Vitamin D Resistant Rickets: 12,000 to 500,000 USP units daily. Hypoparathyroidism: 50,000 to 200,000 USP units daily concomitantly with calcium lactate 4 g, six times per day. DOSAGE MUST BE INDIVIDUALIZED UNDER CLOSE MEDICAL SUPERVISION. Calcium intake should be adequate. Blood calcium and phosphorous determinations must be made every 2 weeks or more frequently if necessary. X-rays of the bones should be taken every month until condition is corrected and stabilized.

Hypersensitivity to vitamin D may be one etiologic factor in infants with idiopathic hypercalcemia. In these cases vitamin D must be strictly restricted. Keep out of the reach of children.

Hypervitaminosis D is characterized by effects on the following organ system: Renal: Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized vascular calcification, or irreversible renal insufficiency which may result in death. CNS: Mental retardation. Soft Tissues: Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs. Skeletal: Bone demineralization (osteoporosis) in adults occurs concomitantly. Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism), vague aches, stiffness, and weakness. Gastrointestinal: Nausea, anorexia, constipation. Metabolic: Mild acidosis, anemia, weight loss. To report SUSPECTED ADVERSE REACTIONS, contact Bionpharma at 1-888-235-2466 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

The effects of administered vitamin D can persist for two or more months after cessation of treatment. Hypervitaminosis D is characterized by: Hypercalcemia with anorexia, nausea, weakness, weight loss, vague aches and stiffness, constipation, mental retardation, anemia, and mild acidosis. Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized vascular calcification, or irreversible renal insufficiency which may result in death. Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs. Bone demineralization (osteoporosis) in adults occurs concomitantly. Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism). The treatment of hypervitaminosis D with hypercalcemia consists in immediate withdrawal of the vitamin, a low calcium diet, generous intake of fluids, along with symptomatic and supportive treatment. Hypercalcemic crisis with dehydration, stupor, coma, and azotemia requires more vigorous treatment. The first step should be hydration of the patient.

1. 1Headache557.9%
2. 2Nausea547.8%
3. 3Dizziness537.6%
4. 4Fatigue507.2%
5. 5Arthralgia466.6%
6. 6Pain375.3%
7. 7Pruritus355.0%
8. 8Dyspnoea344.9%
9. 9Insomnia334.8%
10. 10Diarrhoea314.5%
11. 11Pain In Extremity314.5%
12. 12Rash314.5%
13. 13Drug Ineffective304.3%
14. 14Feeling Abnormal304.3%
15. 15Anxiety243.5%

Recent PubMed references pinned to Vitamin D as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Intravital Monitoring of Psoriasis Treatment Response and Drug Delivery Using Multiphoton Fluorescence Lifetime Imaging.
  Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2026 · Nguyen L, Mess C, Herberger K, et al.
  PMID 42277626DOI 10.1111/srt.70367
• Uric acid, vitamin D, and left ventricular hypertrophy: Unveiling cardiovascular risks - a retrospective cross-sectional study.
  Medicine · 2026 · Abdallah EA, Elzorkany KMA, AlSahlawi M, et al.
  PMID 42260814DOI 10.1097/MD.0000000000049086
• Inflammation, anemia, and vitamin D levels associate with infant thrombocytosis risk.
  Research and practice in thrombosis and haemostasis · 2026 · Rajagopalan SS, Dulmovits BM, Devine M, et al.
  PMID 42254465DOI 10.1016/j.rpth.2026.106644
• Genetically Predicted 25-Hydroxyvitamin D Levels on Hypothyroidism: A Two-Sample Mendelian Randomization.
  BioMed research international · 2026 · Akbarzadeh M, Fateh ST, Moeinafshar A, et al.
  PMID 42253156DOI 10.1155/bmri/8086558
• Is vitamin D the missing link in recurrent urinary tract infections in children? A prospective study.
  World journal of urology · 2026 · Özçift B, Kantar A
  PMID 42234117DOI 10.1007/s00345-026-06509-8
• Exploring associations between maternal vitamin D-binding protein, vitamin D, and offspring asthma/recurrent wheeze.
  The American journal of clinical nutrition · 2026 · Boyd SS, Hecker J, Mirzakhani H, et al.
  PMID 42230085DOI 10.1016/j.ajcnut.2025.101188
• Synergistic Renoprotective Effects of Moderate-Intensity Resistance Training and Vitamin D Supplementation on a Type 2 Diabetic Nephropathy Rat Model.
  FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026 · Liu J, Wu C, Zou Q, et al.
  PMID 42227748DOI 10.1096/fj.202504098R
• The Effect of Vitamin D on the Humoral Immune Response of Calves to the Sheeppox Virus Vaccine.
  Archives of Razi Institute · 2025 · Seyed Ali MR, Mohammad Rahim HH, Mohammad N, et al.
  PMID 42226998DOI 10.32598/ARI.80.5.3611

The 10 most recently updated of 3,496 ClinicalTrials.gov registrations naming Vitamin D as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Host-Diet-Gut Interaction Post Vegan Diet in Pediatric Autoimmune Hepatitis.
  Recruiting · Interventional · 40 enrolled · Institute of Liver and Biliary Sciences, India
  NCT07118657updated 2026-06-12
• Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
  Recruiting · Phase 3 · Interventional · 478 enrolled · National Cancer Institute (NCI)
  NCT06172296updated 2026-06-12
• Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid
  Completed · Phase 4 · Interventional · 47 enrolled · Centre Hospitalier Universitaire, Amiens
  NCT03926377updated 2026-06-12
• Vitamin D in Diabetic Neuropathy
  Not yet recruiting · Phase 2 · Phase 3 · Interventional · 150 enrolled · Tanta University
  NCT07644520updated 2026-06-12
• Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
  Active not recruiting · Phase 3 · Interventional · 67 enrolled · Calcilytix Therapeutics, Inc., a BridgeBio company
  NCT05680818updated 2026-06-11
• Randomized Trial of Enteral Vitamin D Supplementation in Infants < 28 Weeks Gestational Age or <1000 Grams Birth Weight
  Active not recruiting · Interventional · 60 enrolled · The University of Texas Health Science Center, Houston
  NCT05694689updated 2026-06-11
• Effects of High-Dose Vitamin D on Hormones, Neuromuscular Function, Cognition, and Body Composition in Athletes
  Recruiting · Interventional · 200 enrolled · The Jerzy Kukuczka Academy of Physical Education in Katowice
  NCT07641075updated 2026-06-11
• The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes
  Active not recruiting · Interventional · 69 enrolled · University of Pittsburgh
  NCT01047735updated 2026-06-11
• ViDES Trial (Vitamin D Extra Supplementation)
  Active not recruiting · Interventional · 180 enrolled · The University of Texas Health Science Center, Houston
  NCT05459298updated 2026-06-11
• The Effect of Vitamin D Supplementation on the Anti-inflammatory Response in Periodontal Diseases
  Recruiting · Interventional · 120 enrolled · Recep Tayyip Erdogan University Training and Research Hospital
  NCT07636733updated 2026-06-10

Frequently asked questions

What is Vitamin D used for?

According to FDA labeling, Vitamin D carries indications including: Ergocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What are the contraindications for Vitamin D?

Vitamin D labeling lists contraindications including: Ergocalciferol is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.. Always consult the full prescribing information and a clinician.